The establishment for the nonalcoholic steatohepatitis model mice and the analysis for the pathogenesis of the diseases

重点研究金-硫代葡萄糖（GTG）诱导暴饮暴食和肥胖的动物模型，并尝试建立非酒精性脂肪性肝炎（NASH）动物模型，分析其发病机制。经GTG处理的小鼠肝脏逐渐发生纤维化、炎症，瘦素和TNF-a水平随体脂肪的发展而升高。我们建立GTG的受体GPR7，敲除小鼠，并进行分析。基因敲除小鼠表现出肝脏的特殊特征，如暴饮暴食和肥胖的NASH。我们致力于寻找治疗NASH的有效药物。我们最近提出血管紧张素AT1受体阻滞剂（ARB）对减少甲硫肽胆碱缺乏饮食诱导的NASH模型中肝纤维化和肝脂肪变性的发展具有有效性。我们还在研究ARB是否对GTG敲除小鼠的肝纤维化和肝脂肪变性也有减轻作用。此外，我们将重点放在bouhu - su-sho-san作为NASH的另一候选药物。通过使用该药物不仅可以减轻肝纤维化和肝脂肪变性，还可以减轻胰岛素抵抗和降低体脂，我们获得了NASH模型有效性的良好数据。我们可以在不久的将来提供好的数据。

We focused on that Gold-thioglucose (GTG) induced overeating and obesity for animal models, and tried to establish the animal models for nonalcoholic steatohepatitis (NASH) and analyzed the pathogenesis of the disease. The GTG treated mice have been shown that that's livers gradually developed the fibrotic changes, inflammations and the elevation of leptin and TNF-a according to the body fat development. We established the GPR7,the receptor for GTG, knockout mice, and working on the analysis. The knockout mice showed the specialized characteristics in the livers as NASH with overeating and obesity. We work on the searching the effective medicine for attenuating NASH.We recently presented that angiotensin AT1 receptor blocker (ARB) have the effectiveness for the attenuating the development of the hepatic fibrosis and hepatic steatosis in the methionin-cholin deficient diets induced NASH model. We also are going on the research whether ARB also have effectiveness for the attenuating the hepatic fibrosis and hepatic steatosis on GTG knockout mice or not. Moreover, we focus on Bou-hu-tsu-sho-san as another candidate of the medicine for NASH. We are getting the good data for the effectiveness for NASH models by using the medicine not only for the attenuating hepatic fibrosis and hepatic steatosis but also attenuating insulin resistances and the decreasing the body fat.We can present the good data in the near future.